Physician profile
Harry H Blanke
NPI 1104347053
$1,937.99
in general payments reported to CMS, 2019-2025
21 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.64 · 2020: $57.14 · 2021: $111 · 2022: $327 · 2023: $534 · 2024: $532 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $469.88 | 2020-2025 | |
| Novo Nordisk INC | $296.92 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $143.51 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $129.88 | 2023-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $120.64 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.27 | 2022-2023 | |
| Abbott Laboratories | $97.41 | 2022-2025 | Freestyle Libre 3 |
| Si-Bone, INC. | $74.11 | 2024 | |
| Merck Sharp & Dohme LLC | $68.97 | 2021-2025 | Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $62.06 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $51.20 | 2023-2025 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $47.91 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $47.12 | 2023-2024 | Xarelto |
| Amgen INC. | $44.37 | 2024 | Evenity, Prolia, Repatha |
| Gilead Sciences, INC. | $43.19 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $25.58 | 2023 | Heplisav-B |
| Medtronic, INC. | $22.83 | 2022 | |
| Verona Pharma, INC. | $22.04 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $20.40 | 2024 | Veozah |
| Shockwave Medical, INC | $19.03 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Genentech USA, INC. | $16.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Blanke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.